Imetelstat, sold under the brand name Rytelo, is an anti-cancer medication used for the treatment of myelodysplastic syndromes with transfusion-dependent anemia. [1] Imetelstat is an …

On June 6, 2024, the Food and Drug Administration approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk ...

RYTELO™ (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more …

2024年7月16日 · Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion …

RYTELO (imetelstat) for injection, for intravenous use. Initial U.S. Approval: 2024 INDICATIONS AND USAGE RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of …

2024年7月25日 · Imetelstat is used in adults to treat myelodysplastic syndromes with a certain type of anemia that requires a transfusion and it is usually given after other treatments have …

2024年1月20日 · Imetelstat offers a novel mechanism of action with durable transfusion independence (approximately 1 year) and disease-modifying activity for heavily transfused …

2015年6月8日 · This website collects academic, clinical and commercial information about the new drug imetelstat : the first telomerase inhibitor in clinical stage development. Imetelstat …

2025年3月1日 · Imetelstat injection is used to treat low to intermediate-1 risk myelodysplastic syndrome (MDS) in patients with anemia who need blood transfusions and who did not …

2024年8月20日 · Imetelstat (RYTELO™), an oligonucleotide telomerase inhibitor, is being developed by Geron Corporation for the treatment of myeloid hematologic malignancies. In …